Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Indian Firms Expand Discovery Services

by Michael McCoy
January 26, 2009 | A version of this story appeared in Volume 87, Issue 4

Two Indian contract research firms are adding drug discovery services through partnerships with U.S. companies. Syngene International will work with San Diego's Sapient Discovery to offer protein structure-based drug discovery and optimization services. Using X-ray crystallography and proprietary algorithms, Sapient defines the molecular structure of potential drug targets from gene sequence information. Jubilant Biosys, meanwhile, is working with BioLeap of New Hope, Pa., to offer computational fragment-based drug design. The partners say BioLeap's in silico technology is faster and cheaper than traditional screening methods.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.